Efforts to use whole-genome analysis of childhood cancer to improve treatment are spreading, and one case illustrates how genetic testing was linked to clinical research.
The use of genetic panel testing to examine information on several hundred genes at an early stage of treatment is gaining ground in childhood cancer. The aim is to expand the options for personalized treatment, while the specific operation of the testing and the research framework have also been reported.
In one case, the eldest daughter of a company employee, Ms Suganō, in Adachi Ward, Tokyo, was 2 months old in 2022 when she was found to have a cold sensation in her body and cerebral hemorrhaging. After being treated at a nearby hospital, she was transferred to the University of Tokyo Hospital. She underwent surgery to remove a tumor to investigate the cause of the cerebral tumor and hemorrhage, and Motohiro Kato (加藤元博) of the University of Tokyo proposed that she participate in clinical research involving genetic testing.
The article focuses on efforts to advance whole-genome analysis of childhood cancer as research, describing the use of testing in clinical settings and the significance of participating in research. The initiative promoted by Motohiro Kato (加藤元博) is presented as one example of how genetic information can be linked to treatment decisions.